$8.355
-0.104 (-1.24%)終値時点
HBIO のニュース
HBIO のイベント
Sees Q2 Adjusted Gross Margin Between 57%-59%
Sees Q2 adjusted gross margin between 57%-59%. Sees Q2 adjusted EBITDA between $1M-$2M. Expects year-over-year revenue growth in the mid-single digit range at the midpoint of guidance.
Reaffirms FY26 Adjusted Gross Margin Outlook Between 58%-60%
Reaffirms FY26 adjusted gross margin outlook between 58%060% and adjusted EBITDA growth between 6%-10%.
Company Reports Q1 Revenue of $20.8M
Reports Q1 revenue $20.8M vs. $21.8M last year. The company noted encouraging adoption rates within its NPI portfolio, specifically the MeshMEA organoid platform and BTX Electroporation systems, which is driving a shift toward a higher-margin product mix. "First quarter revenues were in line with our expectations and gross margin expanded year-over-year, while we remained profitable on an adjusted EBITDA basis," said CEO John Duke.
Company Expects Adjusted EBITDA Between $1.0 Million and $2.2 Million
The Company expects: Adjusted EBITDA between $1.0 million and $2.2 million
Mark Frost Appointed CFO on Permanent Basis
Interim CFO Mark Frost Appointed CFO on Permanent Basis
関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。